{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05904236",
            "orgStudyIdInfo": {
                "id": "1042-CLN01"
            },
            "organization": {
                "fullName": "IconOVir Bio",
                "class": "INDUSTRY"
            },
            "briefTitle": "Safety and Tolerability of Intravenous Administration of ICVB-1042",
            "officialTitle": "Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients With Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "safety-and-tolerability-of-intravenous-administration-of-icvb"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-10",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-05-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-05-23",
            "studyFirstSubmitQcDate": "2023-06-06",
            "studyFirstPostDateStruct": {
                "date": "2023-06-15",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-10-30",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-01",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "IconOVir Bio",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Study to evaluate the safety and tolerability of intravenous ICVB-1042"
        },
        "conditionsModule": {
            "conditions": [
                "Patients With Advanced Solid Tumors"
            ],
            "keywords": [
                "Oncolytic virus",
                "First in human",
                "Relapsed solid tumor",
                "Refractory solid tumor",
                "Tumor biopsy",
                "Novel therapy",
                "Metastatic",
                "Previously treated"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Escalating doses",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 44,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "ICVB-1042",
                    "type": "EXPERIMENTAL",
                    "description": "Part A: Dose escalation Part B: Dose expansion",
                    "interventionNames": [
                        "Drug: Treatment with ICVB-1042 administered intravenously"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Treatment with ICVB-1042 administered intravenously",
                    "description": "Part A Dose Escalation to assess safety and tolerability of ascending dose levels, define the maximum tolerated dose (MTD), and expansion dose(s) Part B Dose Expansion to further assess safety and tolerability of 1 or more dose levels",
                    "armGroupLabels": [
                        "ICVB-1042"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety of intravenous ICVB-1042",
                    "description": "Assessment of treatment-emergent dose limiting toxicity",
                    "timeFrame": "From dose administration through 12 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Concentration profile of ICVB-1042 in plasma",
                    "timeFrame": "Up to 48 hours after drug infusion"
                },
                {
                    "measure": "Determine immunogenicity of ICVB-1042",
                    "description": "Assessment of anti-drug antibody titer",
                    "timeFrame": "From dose administration through 12 weeks"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Evaluate shedding of ICVB-1042",
                    "description": "ICVB-1042 concentration in urine, feces, and saliva",
                    "timeFrame": "At study visits from dose administration through 12 weeks"
                },
                {
                    "measure": "Tumor response by RECIST criteria",
                    "description": "Number of patients with complete response, partial response, stable disease or progressive disease will be assessed by tumor imaging",
                    "timeFrame": "Day 57"
                },
                {
                    "measure": "Concentration of ICVB-1042 in tumor biopsy",
                    "description": "Measurement of ICVB-1042 in biopsy samples",
                    "timeFrame": "Day 57"
                },
                {
                    "measure": "Number of patients with immunoreactivity to ICVB-1042 administration",
                    "description": "Evaluation of cytokine changes from baseline",
                    "timeFrame": "At study visits from dose administration through 12 weeks"
                },
                {
                    "measure": "Number of patients with changes in cell-free tumor DNA",
                    "description": "Assessment of tumor DNA in plasma",
                    "timeFrame": "At study visits on Day 1, Day 10, Day 29, Day 57, Day 85 or Early Termination visit"
                },
                {
                    "measure": "Evaluate viral replication",
                    "description": "Levels of viral proteins in plasma",
                    "timeFrame": "At study visits from dose administration through 12 weeks"
                },
                {
                    "measure": "Viral titer of ICVB-1042",
                    "description": "Evaluation of infectivity from plasma and saliva samples",
                    "timeFrame": "At study visits from dose administration through 12 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult patients with relapsed or refractory locally advanced or metastatic solid tumors who have progressed on or after at least one prior line of standard of care therapy including immune checkpoint inhibitors and targeted therapies for known molecular alterations if present\n* Measurable disease according to RECIST v1.1\n* ECOG Performance Status 0 or 1\n* Life expectancy of at least 3 months\n\nExclusion Criteria:\n\n* Prior SOC or other treatment with a biologic (eg, mAb) within 28 days prior to dosing or 5\u00d7half-life, whichever is longer from investigational therapy\n* Major surgical procedures within 28 days prior to dosing\n* Limited field irradiation for palliation within 14 days prior to dosing\n* Anti-viral agents, vaccinations within 28 days prior to dosing\n* Known central nervous system (CNS) metastases unless adequately treated and clinically stable without steroids for \u226514 days\n* Leptomeningeal carcinomatosis\n* Pulmonary lymphangitic spread of cancer\n* History of clinically significant cardiovascular abnormalities\n* Known active infection requiring systemic antibiotic therapy or systemic antifungal therapy\n* Known active HIV, hepatitis B or C, or other active viral disease\n* Known hematologic malignancies (requiring or not requiring active therapy).\n* Requirement for immunosuppressive therapy (ie, prednisone equivalent of \\>10 mg/day)\n* Women who are pregnant or lactating\n* Oxygen saturation measured with Pulse oximeter \\<90% and/or on supplemental O2",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "IconOVir Study Team",
                    "role": "CONTACT",
                    "phone": "858 293-5611",
                    "email": "CLN01trial@iconovir.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Julie Maltzman, MD",
                    "affiliation": "IconOVir Bio",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "California Cancer Associates",
                    "status": "RECRUITING",
                    "city": "San Marcos",
                    "state": "California",
                    "zip": "92069",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.14337,
                        "lon": -117.16614
                    }
                },
                {
                    "facility": "Karmanos Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48201",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "NYU Langone Health, Perlmutter Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "University of North Carolina Lineberger Comprehensive Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Chapel Hill",
                    "state": "North Carolina",
                    "zip": "27599",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.9132,
                        "lon": -79.05584
                    }
                },
                {
                    "facility": "Carolina BioOncology",
                    "status": "RECRUITING",
                    "city": "Huntersville",
                    "state": "North Carolina",
                    "zip": "28078",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.41069,
                        "lon": -80.84285
                    }
                },
                {
                    "facility": "University of Pennsylvania, Abramson Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "Sarah Cannon Research Institute",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Next Oncology, Dallas",
                    "status": "RECRUITING",
                    "city": "Irving",
                    "state": "Texas",
                    "zip": "75039",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.81402,
                        "lon": -96.94889
                    }
                },
                {
                    "facility": "Next Oncology, San Antonio",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "Next Oncology, Virginia",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}